Antiviral activity of the drug based on the complex of single-stranded high-polymer RNA against the rabies virus in vitro
- Авторлар: Generalov S.V.1, Perevoznikov D.A.1, Abramova Е.G.1,2, Nikiforov A.K.1,2, Spitsyn A.A.3, Potupchik T.V.4, Shenderovich Е.M.5
-
Мекемелер:
- Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
- Saratov State University of Genetics, Biotechnology and Engineering named after N.I. Vavilov
- Limited Liability Company «SPA Evolution of Nature»
- Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russian Federation
- The Gamaleya National Center of Epidemiology and Microbiology
- Шығарылым: Том 28, № 8 (2025)
- Беттер: 38-44
- Бөлім: Biological chemistry
- URL: https://journal-vniispk.ru/1560-9596/article/view/310627
- DOI: https://doi.org/10.29296/25877313-2025-08-05
- ID: 310627
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Тек жазылушылар үшін
Аннотация
Introduction. Rabies is an infectious disease with absolute mortality. Currently, there are no effective drugs and treatment regimens for people with signs of rabies. The only strategy for post-exposure rabies prevention is vaccination and administration of rabies immunoglobulin. At the same time, the search for new treatment and prevention regimens for the disease remains relevant, which is why the development and study of antiviral drugs effective against the rabies virus is relevant.
Objective of the study. To study the antiviral activity of a drug based on single-stranded high-polymer RNA of Sacharomyces cerevisiae, which has previously shown antiviral activity against other pathogens of viral infections.
Material and methods. The work investigated the effect of the drug based on single-stranded high-polymer RNA of S. cerevisiae "Amphievovir" on the level of reproduction of the attenuated rabies virus strain "Saratov" on the Vero cell culture model.
Results. The studied drug in the concentration range from 10 to 20 μg/ml and added to the cell culture no later than 24 hours after infection reduces the titer of the virus by 24.6 to 36.2% compared to the control group. Adding the drug to the infected cell culture later than 24 hours reduces its antiviral effect.
Conclusions. The studied drug based on single-stranded high-polymer RNA of S. cerevisiae has antiviral activity against the rabies virus in vitro. The results allow us to justify further study of post-exposure rabies prophylaxis regimens using drugs based on immunostimulating and immunomodulatory RNA.
Негізгі сөздер
Толық мәтін
##article.viewOnOriginalSite##Авторлар туралы
S. Generalov
Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Хат алмасуға жауапты Автор.
Email: svgeneraloff@gmail.com
ORCID iD: 0000-0003-1461-5383
SPIN-код: 4130-2475
Ph.D. (Biol.), Leading Research Scientist, Laboratory of Preventive Immunoglobulins
Ресей, Universitetskaya St., 46, Saratov, 410005D. Perevoznikov
Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: rusrapi@microbe.ru
Master's Student, Laboratory Assistant-Researcher, Laboratory of Preventive Immunoglobulins
Ресей, Universitetskaya St., 46, Saratov, 410005Е. Abramova
Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saratov State University of Genetics, Biotechnology and Engineering named after N.I. Vavilov
Email: rusrapi@microbe.ru
ORCID iD: 0000-0002-8798-1547
SPIN-код: 3382-3399
Dr.Sc. (Biol.), Head of the Laboratory of Preventive Immunoglobulins
Ресей, Universitetskaya St., 46, Saratov, 410005; Pyotr Stolypin Avenue, building 4, building 3, Saratov, 410012A. Nikiforov
Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saratov State University of Genetics, Biotechnology and Engineering named after N.I. Vavilov
Email: rusrapi@microbe.ru
ORCID iD: 0000-0002-1130-3504
SPIN-код: 3202-3979
Dr.Sc. (Biol.), Professor, Deputy Director for Experimental and Production Work
Ресей, Universitetskaya St., 46, Saratov, 410005; Pyotr Stolypin Avenue, building 4, building 3, Saratov, 410012A. Spitsyn
Limited Liability Company «SPA Evolution of Nature»
Email: evoprirody@yandex.ru
ORCID iD: 0009-0005-4900-826X
Chief Research Scientist
Ресей, Voskhod St. 20/1, room 1.2, Novosibirsk, 630102T. Potupchik
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russian Federation
Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-код: 8353-3513
Ph.D. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology with a postgraduate course
Ресей, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022Е. Shenderovich
The Gamaleya National Center of Epidemiology and Microbiology
Email: rusrapi@microbe.ru
ORCID iD: 0009-0003-3382-1411
Laboratory Research Assistant, Laboratory of Indication and Ultrastructural Analysis of Microorganisms
Ресей, Gamaleyi street, building 18, Moscow, 123098Әдебиет тізімі
- Zheng J., Sui B., Zhao L. Rabies lyssavirus. Veterinary Virology of Domestic and Pet Animals. Cham: Springer Nature Switzerland, 2025; 1–19.
- WHO Expert Consultation on Rabies, third report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1012). 195
- Lacy M., Phasuk N., Scholand S.J. Human Rabies Treatment – From Palliation to Promise. Viruses. 2024; 16(1):160. doi: 10.3390/v16010160
- Kovalev N.A., Buchukuri D.V. Izuchenie beshenstva i razrabotka sredstv i sposobov ego profilaktiki v Belarusi. Vescі Nacyyanal'naj akademіі navuk Belarusі. Seryya agrarnyh navuk. 2014; 4: 96–102. (In Russ.).
- Buchukuri D.V., Kovalev N.A., Lomako Yu.V. i dr. Vakcinosoderzhashchaya bezblisternaya primanka dlya peroral'noj immunizacii plotoyadnyh zhivotnyh protiv beshenstva. Izvestiya Nacional'noj akademii nauk Belarusi. Seriya agrarnyh nauk. 2019; 57(3): 334–343. (In Russ.).
- Yamada K., Noguchi K., Kimitsuki K., et al. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral Res. 2019; 172: 104641. doi: 10.1016/j.antiviral.2019.104641.
- Wu J., Cao S., Lei S., et al. Clofazimine: a promising inhibitor of rabies virus. front pharmacol. 2021; 12: 598241. doi: 10.3389/fphar.2021.598241.
- Scott T.P., Nel L.H. Rabies prophylactic and treatment options: an in vitro study of sirna- and aptamer-based therapeutics. Viruses. 2021; 13(5): 881. doi: 10.3390/v13050881
- Brandão P.E., Castilho J.G., Fahl W., et al. Short-interfering RNAs as antivirals against rabies. Braz. J. Infect. Dis. 2007; 11(2): 224–225. doi: 10.1590/s1413-86702007000200011.
- Ermolaev V.V., Shimina G.G., Alikin Yu.S. i dr. Novye preparaty immunomodulyatorov na osnove RNK dlya lecheniya virusnyh infekcij. Innovacii i prodovol'stvennaya bezopasnost'. 2023; 4: 78–89. DOI.org/10.31677/2311-0651-2023-42-4-78-89. (In Russ.).
- Danilenko E.D., Belkina A.O., Sysoeva G.M. Sozdanie lekarstvennyh preparatov na osnove vysokopolimernyh dvuspiral'nyh RNK dlya protivovirusnoj i protivoopuholevoj terapii. Biomedicinskaya himiya. 2019; 65(4): 277–293. (In Russ.).
- Starkov F.I., Shalin V.V., Mironov V.S., Mironov A.V. Miluokskij protokol – ot idei do realizacii. Medicinskij vestnik Yuga Rossii. 2023; 14(3): 59–65. doi: 10.21886/2219-8075-2023-14-3-59-65. (In Russ.).
- Ignat'ev G.M., Shustova E.Yu., Rogozhina E.A. i dr. Protivovirusnaya aktivnost' lekarstvennogo preparata na osnove RNK dvuspiral'noj natrievoj soli v otnoshenii SARS-CoV-2 in vitro. BIOpreparaty. Profilaktika, diagnostika, lechenie. 2023; 23(3): 290–299. doi: 10.30895/2221-996X-2023-23-3-290-299. (In Russ.).
- Yamkovaya T.V., Mazurkova N.A., Zagrebel'nyj S.N. i dr. Sposob lecheniya ospy. Patent № 2480219. opubl. 27.04.2013. Byul. №12. (In Russ.).
- Yamkovaya T.V., Glotova T.I., Kolesnikova O.P. i dr. Legko pronikayushchij cherez biologicheskie membrany mylkij amfifil'nyj induktor interferona γ-perspektivnyj preparat dlya lecheniya gepatita s cheloveka. Sibirskij nauchnyj medicinskij zhurnal. 2014. 34(1): 15–20. (In Russ.).
Қосымша файлдар
